What is NeRRe Therapeutics?
NeRRe Therapeutics is a UK-based clinical-stage company dedicated to developing orvepitant, a novel neurokinin-1 receptor antagonist. The company's primary focus is on addressing debilitating cough hypersensitivity disorders, particularly idiopathic pulmonary fibrosis (IPF), a rare and terminal lung disease for which no approved treatments currently exist. Established in 2012 as a spin-out from GSK, NeRRe Therapeutics leverages its experienced management team and backing from prominent life sciences investors to advance its innovative therapeutic approach. The company's commitment lies in progressing orvepitant through rigorous preclinical and clinical development stages to meet an unmet medical need.
How much funding has NeRRe Therapeutics raised?
NeRRe Therapeutics has raised a total of $36.3M across 2 funding rounds:
Series A
$8.1M
Series B
$28.2M
Series A (2012): $8.1M, investors not publicly disclosed
Series B (2017): $28.2M led by Novo A/S, OrbiMed, Forbion, Advent Life Sciences, and Fountain Healthcare Partners
Key Investors in NeRRe Therapeutics
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on investments within the life sciences sector.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise across the healthcare sector, managing capital for biopharmaceuticals, medical devices, digital health, and diagnostics.
Forbion
Forbion is a global life sciences venture capital firm that builds and guides biotech and biopharmaceutical companies from early stage through clinical development, with a focus on innovative therapeutics.
What's next for NeRRe Therapeutics?
With the recent infusion of major strategic capital, NeRRe Therapeutics is poised to advance its clinical development programs. The enterprise-level funding suggests a focus on scaling operations and potentially preparing for later-stage clinical trials or commercialization efforts. The company's strategic direction will likely involve further validation of orvepitant's efficacy and safety profile in patients suffering from chronic cough associated with IPF. Continued investment in this area highlights the growing interest in addressing rare respiratory diseases and the potential for significant returns in the biopharmaceutical sector.
See full NeRRe Therapeutics company page
